MicroRNA 1294 (miR-1294)

MicroRNA 1294 (miR-1294) is an endogenous small non-coding RNA (miRNA) that post-transcriptionally regulates gene expression by binding to the 3′ untranslated region (UTR) of target mRNAs, leading to inhibition of translation or mRNA degradation. It is widely recognized as a tumor suppressor and has been found to be significantly downregulated in several cancer types, where it inhibits cell proliferation, migration, and invasion, and promotes apoptosis[1][2]. miR-1294 regulates key oncogenic pathways such as PI3K/AKT/mTOR, RAS, and JAK/STAT by targeting genes including c-Myc, IGF1R, AKT, FGFR1, and PIM1[1][2]. Downregulation of miR-1294 is linked to poor prognosis and increased resistance to chemotherapy agents such as cisplatin and temozolomide in various malignancies, including oral squamous cell carcinoma, gastric cancer, ovarian cancer, and others[1][2]. Although miR-1294 is not currently the direct target of approved drugs, its modulation offers potential as a therapeutic approach, especially using RNA-based delivery strategies, and it is being investigated as a biomarker for cancer and drug resistance monitoring[1][2].

Other names

hsa-mir-1294MIRN1294mir-1294MIR1294

Drugs do not directly target miR-1294, but low levels of miR-1294 are associated with resistance to chemotherapy agents such as cisplatin and temozolomide[1]